Efficacy and safety of FLAG regimen in the treatment of relapsed acute myeloid leukemia

Objective To analyze the curative effect and safety of FLAG regimen in the treatment of relapsed acute myeloid leukemia (AML). Methods 70 patients with refractory recurrent AML treated in our hospital from July 2013 to July 2016 were selected and randomly divided into study group and control group. 35 cases in the study group were treated with FLAG regimen, while 35 cases in the control group were treated with MEA regimen. After one course of treatment, the clinical efficacy and adverse reactions of the two groups were compared. Results After 1 course of treatment, the total effective rate in the study group was 74.29%, which was higher than 51.43% in the control group, with statistically significant difference (χ2=3.92, P 0.05); the total incidence of non-hematologic adverse reactions in the study group was 68.57%, which was significantly lower than 91.43% in the control group, with statistically significant difference (P<0.05). Conclusion The FLAG regimen in the treatment of refractory recurrent AML has high clinical efficacy, with low incidence of adverse reactions and high safety, worthy of clinical application and promotion. Key words: FLAG regimen; Acute myeloid leukemia; Clinical efficacy; Safety